SEATTLE — December 4, 2020 — Seattle Cancer Care Alliance (SCCA), the only National Comprehensive Cancer Network (NCCN)-designated cancer center in Washington state, announced that its clinicians will present new research at the 62nd Annual Meeting of the American Society of Hematology, which is being held virtually December 5-8, 2020.
SCCA clinicians and researchers will share perspectives and data on a range of topics related to treatments for patients with hematologic malignancies. This includes outcomes and utilization of various therapies in multiple myeloma, results from immunotherapy clinical trials and perspectives from patient-reported outcomes in CAR-T cell therapy. Other findings being presented are related to treating refractory follicular lymphoma, liso-cel vs. axi-cel in large B-cell lymphoma (LBCL), and personalized cancer care across hematology. Additionally, SCCA clinicians who have been at the forefront of the global pandemic will be sharing key learnings on the severity of and management of COVID-19 in hematology patients.
“Furthering advances in cancer care is at the core of SCCA’s mission,” said Nancy Davidson, MD, president and executive director of Seattle Cancer Care Alliance. “Our team’s deep expertise in the treatment of blood cancers and related conditions is highlighted through our clinicians' presentations and posters at this year’s ASH conference. This work builds on our legacy and foundation of delivering world class cancer care for hematologic malignancies.”
“Each year the ASH Annual Meeting brings together the latest research and developments in hematology,” said Stephanie J. Lee, MD, physician at Seattle Cancer Care Alliance and 2020 President of the American Society of Hematology. “And while this year’s meeting had to shift to a virtual platform, I am looking forward to hearing about new findings and collaborating with our members to explore crucial issues in our field. These advances will improve the treatment options for those with hematological malignancies.”
Stephanie J. Lee, MD will host a special fireside chat during the conference with Dr. Anthony Fauci to discuss his views about the COVID-19 pandemic. The chat will take place from 10 to 10:30 a.m. Eastern on Dec. 5.
Highlighted below is a list of SCCA’s lead abstracts, presentations and workshops:
Abstracts
Improving cellular therapy outcomes
High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics
Abstract: 1442
SCCA author: Jordan Gauthier, MD, MSc
Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Abstract: 1443
SCCA author: Mazyar Shadman, MD, MPH
Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Abstract: 2116
SCCA author: David G. Maloney, MD, PhD, Medical Director, Cellular Immunotherapy
Phase I Study of Adoptive Immunotherapy with HA-1-Specific CD8+ and CD4+ Memory T Cells for Children and Adults with Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation (HCT): Trial in Progress
Abstract: 492
SCCA author: Elizabeth F Krakow, MD, MSc
Patient-Reported Outcomes at Time of CAR-T Cell Therapy
Abstract: 3485
SCCA author: Erin Mullane, ARNP
Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma
Abstract: 3084
SCCA author: Jordan Gauthier, MD
Clinical Experience of Tabelecleucel in Patients with Life-Threatening Complications of Epstein-Barr Virus Viremia
Abstract: 2554
SCCA author: Ann Dahlberg, MD
Insights into treatment of hematologic malignancies
Ixazomib-Rituximab in Untreated Indolent B-NHL: An Effective, Very Low Toxicity Regimen
Abstract: 2051
SCCA author: Solomon A. Graf, MD
Comparison of Outcomes and Utilization of Therapy in Multiple Myeloma Patients in the USA and Alberta, Canada
Abstract: 2516
SCCA author: Andrew J. Cowan, MD
Pembrolizumab with R-CHOP in Previously Untreated Diffuse Large B-Cell Lymphoma: Long Term Follow up and Analysis of the Mechanism of Pdl-1 Tumor Expression
Abstract: 2111
SCCA author: Stephen D. Smith, MD
A Shared SF3B1 Neoantigen Is Presented on Primary Malignant Cells and Induced Pluripotent Stem Cell-Derived Hematopoietic Lines
Abstract: 3265
SCCA author: Melinda Ann Biernacki, MD
Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib
Abstract: 2947
SCCA author: Mazyar Shadman, MD, MPH
Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
Abstract: 2935
SCCA author: Ryan C. Lynch, MD
Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study
Abstract: 2964
SCCA author: Ryan C. Lynch, MD
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Abstract: 2943
SCCA author: Chaitra S. Ujjani, MD
Multiparameter Flow Cytometry (MFC) of Cerebrospinal Fluid (CSF) from Adults Receiving Hypercvad for Acute Lymphoblastic Leukemia/Lymphoma (ALL) Identifies Patients at Higher Risk of Central Nervous System (CNS) Relapse: A Single-Center Retrospective
Abstract: 584
SCCA author: Kelsey-Leigh A Garcia, Clinical Research Coordinator
Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children’s Oncology Group AAML1031 Protocol
Abstract: 593
SCCA author: Soheil Meshinchi, MD, PhD
Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm-2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies
Abstract: 1142
SCCA author: Ajay Gopal, MD, Medical Director, Clinical Research, Hematology, Malignancies/Hematology
Interaction of Remission Status and Cause of Death in Acute Myeloid Leukemia
Abstract: 1010
SCCA author: Anna B. Halpern, MD
Clinical Benefit and Tolerability of Crenolanib in Children with Relapsed Acute Myeloid Leukemia Harboring Treatment Resistant FLT3 ITD and Variant FLT3 TKD Mutations Treated on Compassionate Access
Abstract: 1973
SCCA author: Soheil Meshinchi, MD, PhD
Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR4.5: Results from ENESTfreedom
Abstract: 2155
SCCA author: Jerald Radich, MD
A Multicenter, Retrospective Study of Accelerated Venetoclax Ramp-up in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Abstract: 3145
SCCA author: Mazyar Shadman, MD, MPH
COVID-19 and Cancer
Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis
Abstract: 1632
SCCA author: Ryan C. Lynch, MD
Worldwide Examination of Patients with CLL Hospitalized for COVID-19 Clinically Relevant Abstract
Abstract: 1590
SCCA author: Chaitra S. Ujjani, MD
Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry
Abstract: 204
SCCA author: Nicole Kuderer, MD
Preventing and treating complications of cancer therapy
Effects of Tranexamic Acid Prophylaxis on Bleeding Outcomes in Hematologic Malignancy: The a-TREAT Trial Clinically Relevant Abstract
Abstract: 2
SCCA author: Terry B. Gernsheimer, MD, Medical Director, Transfusion Services
Phase 1 Study of Axatilimab (SNDX-6352), a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment
Abstract: 358
SCCA author: Stephanie J. Lee, MD, MPH, Research Director of the Transplant Long-Term Follow-Up Program
Pre-Transplant Gene Expression May Predict Risk of Graft Versus Host Disease
Abstract: 420
SCCA author: Merav Bar, MD
Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213)
Abstract: 353
SCCA author: Stephanie Lee, MD
Invited Education and Scientific Program Talks
What Hematologists Need to Know About Giving and Stopping Aspirin
Type: Education Program
SCCA author: David A. Garcia, MD
Caring for Patients with Acute Leukemia in Community Hospitals: Who, What, and When to Refer? - Live Q&A
Type: Education Program
SCCA author: Anna B. Halpern, MD
Challenges in Cell Therapy: Relapse and Toxicities: SCI-2 Addressing Relapsed Disease Following Cellular Therapy
Type: Scientific Program
SCCA author: Aude G. Chapuis, MD
Existing Agents, Novel Agents, or Transplantation for High Risk MDS
Type: Education Program
SCCA author: Bart L. Scott, MD, Clinical Director, MDS/MPN & myeloid malignancies
Updates on the Diagnosis and Management of the Most Common Porphyrias – AIP and EPP
Type: Education Program
SCCA author: Michael Linenberger, MD, Medical Director, Apheresis & Cellular Therapy
Handling Challenging Questions in the Management of CML - Live Q&A
Type: Education Program
SCCA author: Vivian G. Oehler, MD
Workshops
Age, Performance Status, and Comorbidities in Relation to IEC-Associated Toxicities (Including ICANS)*
Type: Scientific Workshop
SCCA Facilitator: Jordan Gauthier, MD
Media Contact:
Heather Platisha
hplatisha@fredhutch.org